Literature DB >> 20534372

Evidence-based management of rapidly progressing systemic sclerosis.

Dinesh Khanna1, Christopher P Denton.   

Abstract

Systemic sclerosis has the highest case-specific mortality of any of the auto-immune rheumatic diseases, as well as causing major morbidity. It is a major clinical challenge and one that has previously provoked substantial nihilism due to the limited therapeutic options available and the perceived lack of evidence for clinical effectiveness of those treatments that are currently in use. However, this situation is changing; there are emerging data supporting efficacy for some treatment approaches for this patient group together with a growing number of exciting potential novel approaches to treatment that are moving into the clinical arena. Some of the recent clinical trials are reviewed and discussed in detail. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20534372      PMCID: PMC2884006          DOI: 10.1016/j.berh.2009.12.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  54 in total

1.  Pulmonary arterial hypertension in systemic sclerosis: diagnostic pathway and therapeutic approach.

Authors:  L Robertson; A Pignone; O Kowal-Bielecka; G Fiori; C P Denton; M Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2005-06       Impact factor: 19.103

2.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Authors:  C P Denton; M Humbert; L Rubin; C M Black
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

3.  Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis.

Authors:  C C Bunn; C P Denton; X Shi-Wen; C Knight; C M Black
Journal:  Br J Rheumatol       Date:  1998-01

4.  Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.

Authors:  Paul J DeMarco; Michael H Weisman; James R Seibold; Daniel E Furst; Weng Kee Wong; Eric L Hurwitz; Maureen Mayes; Barbara White; Fredrick Wigley; Walter Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Philip J Clements
Journal:  Arthritis Rheum       Date:  2002-11

5.  Effect of systemic sclerosis on left ventricular long-axis motion and left ventricular mass assessed by magnetic resonance.

Authors:  S P Karwatowski; N A Chronos; H Sinclaire; S M Forbat; M G St John Sutton; C Black; S R Underwood; D J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2000       Impact factor: 5.364

6.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Authors:  O Kowal-Bielecka; R Landewé; J Avouac; S Chwiesko; I Miniati; L Czirjak; P Clements; C Denton; D Farge; K Fligelstone; I Földvari; D E Furst; U Müller-Ladner; J Seibold; R M Silver; K Takehara; B Garay Toth; A Tyndall; G Valentini; F van den Hoogen; F Wigley; F Zulian; Marco Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

7.  Is pulmonary arterial hypertension really a late complication of systemic sclerosis?

Authors:  Eric Hachulla; David Launay; Luc Mouthon; Olivier Sitbon; Alice Berezne; Loïc Guillevin; Pierre-Yves Hatron; Gérald Simonneau; Pierre Clerson; Marc Humbert
Journal:  Chest       Date:  2009-05-08       Impact factor: 9.410

8.  Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.

Authors:  Dinesh Khanna; Xiaohong Yan; Donald P Tashkin; Daniel E Furst; Robert Elashoff; Michael D Roth; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Philip J Clements
Journal:  Arthritis Rheum       Date:  2007-05

Review 9.  Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).

Authors:  H Sallam; T A McNearney; J D Z Chen
Journal:  Aliment Pharmacol Ther       Date:  2006-03-15       Impact factor: 8.171

10.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.

Authors:  D Mukerjee; D St George; B Coleiro; C Knight; C P Denton; J Davar; C M Black; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

View more
  26 in total

1.  Idiopathic or connective tissue disease-associated interstitial lung disease: a case of HRCT mimicry.

Authors:  Kevin R Flaherty; Dinesh Khanna
Journal:  Thorax       Date:  2014-01-06       Impact factor: 9.139

2.  Work productivity in scleroderma: analysis from the University of California, Los Angeles scleroderma quality of life study.

Authors:  Manjit K Singh; Philip J Clements; Daniel E Furst; Paul Maranian; Dinesh Khanna
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

Review 3.  Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Ivan O Rosas; Paul F Dellaripa; David J Lederer; Dinesh Khanna; Lisa R Young; Fernando J Martinez
Journal:  Ann Am Thorac Soc       Date:  2014-04

4.  The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society.

Authors:  Yaşar Murat Taş; Gözde Derviş Hakim; Pembe Keskinoğlu; Gökçe Kenar; Handan Yarkan; Berrin Zengin; Gerçek Can; Fatoş Önen; Nurullah Akkoç; Merih Birlik; Mesut Akarsu
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

Review 5.  My approach to the treatment of scleroderma.

Authors:  Ami A Shah; Fredrick M Wigley
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

Review 6.  Old medications and new targeted therapies in systemic sclerosis.

Authors:  Vivek Nagaraja; Christopher P Denton; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2014-07-26       Impact factor: 7.580

7.  When there's smoke there's…scleroderma: evidence that patients with scleroderma should stop smoking.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2011-01-08       Impact factor: 5.782

8.  Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise.

Authors:  Jaap Fransen; Sindhu R Johnson; Frank van den Hoogen; Murray Baron; Yannick Allanore; Patricia E Carreira; László Czirják; Christopher P Denton; Oliver Distler; Daniel E Furst; Armando Gabrielli; Ariane Herrick; Murat Inanc; Bashar Kahaleh; Otylia Kowal-Bielecka; Thomas A Medsger; Ulf Mueller-Ladner; Gabriela Riemekasten; Stanislaw Sierakowski; Gabriele Valentini; Doug Veale; Madelon C Vonk; Ulrich Walker; Lorinda Chung; Philip J Clements; David H Collier; Mary E Csuka; Sergio Jimenez; Peter A Merkel; James R Seibold; Richard Silver; Virginia Steen; Alan Tyndall; Marco Matucci-Cerinic; Janet E Pope; Dinesh Khanna
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-03       Impact factor: 4.794

9.  Pulmonary echography in systemic sclerosis.

Authors:  F C Moazedi-Fuerst; P M Zechner; N J Tripolt; S M Kielhauser; K Brickmann; S Scheidl; A Lutfi; W G Graninger
Journal:  Clin Rheumatol       Date:  2012-08-18       Impact factor: 2.980

10.  Indications for hospitalization and in-hospital mortality in Thai systemic sclerosis.

Authors:  Sittichai Netwijitpan; Chingching Foocharoen; Ajanee Mahakkanukrauh; Siraphop Suwannaroj; Ratanavadee Nanagara
Journal:  Clin Rheumatol       Date:  2012-12-08       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.